Synchrotron FTIR micro-spectroscopy for structural analysis of Lewy bodies in the brain of Parkinson's disease patients

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Araki, Katsuya ^a   Yagi, Naoto ^b   Ikemoto, Yuka ^b   Yagi, Hisashi ^c,d   Choong, Chi Jing ^a   Hayakawa, Hideki ^a   Beck, Goichi ^a   Sumi, Hisae ^a   Fujimura, Harutoshi ^e   Moriwaki, Taro ^b   Nagai, Yoshitaka ^f   Goto, Yuji ^c   Mochizuki, Hideki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPAN SYNCHROTRON RADIATION RESEARCH INSTITUTE   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d TOTTORI UNIVERSITY   (Japan)

^e TONEYAMA NATIONAL HOSPITAL   (Japan)

^f NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; SNCA PROTEIN, HUMAN;

AGED; FEMALE; HUMAN; INFRARED SPECTROSCOPY; LEWY BODY; MALE; METABOLISM; PARKINSON DISEASE; PATHOLOGY; SYNCHROTRON; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; FEMALE; HUMANS; LEWY BODIES; MALE; PARKINSON DISEASE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SYNCHROTRONS;

EID: 84949294764     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17625     Document Type: Article

References (50)

1. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., Goedert, M.-Synuclein in filamentous inclusions of Lewy bodies from Parkinson disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. 95, 6469-6473 (1998).
2. Baba, M. et al. Aggregation of-synuclein in Lewy bodies of sporadic Parkinson disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879-884 (1998).
3. Maroteaux, L., Campanelli, J. T., Scheller, R. H. Synuclein-a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 2804-2815 (1988).
4. Iwai, A. et al. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467-475 (1995).
5. Bottner, M. et al. Expression pattern and localization of alpha-synuclein in the human enteric nervous system. Neurobiol. Dis. 48, 474-480 (2012).
6. Barbour, R. et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener. Dis. 5, 55-59 (2008).
7. Fauvet, B. et al. Alpha-synuclein in the central nervous system and from erythrocytes, mammalian cells and E. coli exists predominantly as a disordered monomer. J. Biol. Chem. 287, 15345-15364 (2012).
8. Conway, K. A., Harper, J. D., Lansbury, P. T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to earlyonset Parkinson disease. Nat. Med. 4, 1318-1320 (1998).
9. Giasson, B. I., Uryu, K., Trojanowski, J. Q., Lee, V. M. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274, 7619-7622 (1999).
10. Manning-Bog, A. B. et al. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 277, 1641-1644 (2002).
11. Luk, K. C. et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl. Acad. Sci. USA 106, 20051-20056 (2009).
12. Bousset, L. et al. Structural and functional characterization of two alpha-synuclein strains. Nat. Commun. 4, 2575 (2013).
13. Serpell, L. C., Berriman, J., Jakes, R., Goedert, M., Crowther, R. A. Fiber diffraction of synthetic-synuclein filaments shows amyloid-like cross-conformation. Proc. Natl. Acad. Sci. USA 97, 4897-4902 (2000).
14. Uversky, V. N., Li, J., Fink, A. L. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 276, 10737-10744 (2001).
15. Wood, S. J. et al. Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274, 19509-19512 (1999).
16. Yonetani, M. et al. Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. J. Biol. Chem. 284, 7940-7950 (2009).
17. Luk, K. C. et al. Pathological-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949-953 (2012).
18. Masuda-Suzukake, M. et al. Prion-like spreading of pathological-synuclein in brain. Brain 136, 1128-1138 (2013).
19. Roy, S., Wolman, L. Ultrastructural observations in Parkinsonism. J. Pathol. 99, 39-44 (1969).
20. Galloway, P. G., Mulvihill, P., Perry, G. Filaments of Lewy bodies contain insoluble cytoskeletal elements. Am. J. Pathol. 140, 809-22 (1992).
21. Iwatsubo, T. et al. Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am. J. Pathol. 148, 1517-1529 (1996).
22. Arima, K. et al. T. Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res. 808, 93-100 (1998).
23. Takahashi, H., Wakabayashi, K. The cellular pathology of Parkinson's disease. Neuropathology 21, 315-322 (2001).
24. Shults, C. Lewy bodies. Proc. Natl. Acad. Sci. USA 103, 1661-1668 (2006).
25. Kanazawa, T. et al. Pale Neurites, Premature-Synuclein Aggregates with Centripetal Extension from Axon Collaterals. Brain Pathol. 22, 67-68 (2012).
26. Sakamoto, M. et al. Heterogeneity of nigral and cortical Lewy bodies differentiated by amplified triple-labeling for alphasynuclein, ubiquitin, and thiazin red. Exp. Neurol. 177, 88-94 (2002).
27. Wakabayashi, K. et al. The Lewy body in Parkinson's disease and related neurodegenerative disorders. Mol. Neurobiol. 47, 495-508 (2013).
28. Fändrich, M. On the structural definition of amyloid fibrils and other polypeptide aggregates. Cell Mol. Life Sci. 64, 2066-2078 (2007).
29. Beach, T. G. et al. Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol. 116, 277-88 (2008).
30. Seshadri, S., Khurana, R., Fink, A. L. Fourier transform infrared spectroscopy in analysis of protein deposits. Methods Enzymol. 309, 559-576 (1999).
31. Liao, C. R. et al. Synchrotron FTIR reveals lipid around and within amyloid plaques in transgenic mice and Alzheimer's disease brain. Analyst. 138, 3991-3997 (2013).
32. Choo, L. P. et al. In situ characterization of beta-amyloid in Alzheimer's diseased tissue by synchrotron Fourier transform infrared microspectroscopy. Biophys. J. 71, 1672-1679 (1996).
33. Miller, L. M. et al. Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer's disease. J. Struct. Biol. 155, 30-37 (2006).
34. Tofaris, G. K., Razzaq, A., Ghetti, B., Lilley, K. S., Spillantini, M. G. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem. 278, 44405-11 (2003).
35. Issidorides, M. R., Mytilineou, C., Panayotacopoulou, M. T., Yahr, M. D. Lewy bodies in parkinsonism share components with intraneuronal protein bodies of normal brains. J. Neural. Transm. Park. Dis. Dement. Sect. 3, 49-61 (1991).
36. Vermaas, J. V., Tajkhorshid, E. Conformational heterogeneity of-synuclein in membrane. Biochim. Biophys. Acta. 1838, 3107-3117 (2014).
37. Fusco, G. et al. Direct observation of the three regions in-synuclein that determine its membrane-bound behaviour. Nat. Commun. 5, 3827 (2014).
38. Yasuda, T., Nakata, Y., Mochizuki, H.-Synuclein and neuronal cell death. Mol. Neurobiol. 47, 466-83 (2013).
39. Papp, M. I., Lantos, P. I. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 117, 235-243 (1994).
40. Uchihara, T. et al. Silver stainings distinguish Lewy bodies and glial cytoplasmic inclusions: comparison between Gallyas-Braak and Campbell-Switzer methods. Acta Neuropathol. 110, 255-260 (2005).
41. Ando, Y., Nakamura, M., Araki, S. Transthyretin-related familial amyloidotic polyneuropathy. Arch. Neurol. 62, 1057-1062 (2005).
42. Westermark, P., Andersson, A., Westermark, G. T. Is aggregated IAPP a cause of beta-cell failure in transplanted human pancreatic islets Curr. Diab. Rep. 5, 184-188 (2005).
43. Münch, J. et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 131, 1059-1071 (2007).
44. Brender, J., Salamekh, S., Ramamoorthy, A. Membrane-disruption and early events in the aggregation of the diabetes related peptide IAPP from a molecular perspective. Acc. Chem. Res. 116, 3650-3658 (2012).
45. Brender, J. R. et al. Probing the sources of the apparent irreproducibility of amyloid formation: drastic changes in kinetics and a switch in mechanism due to micellelike oligomer formation at critical concentrations of IAPP. J Phys Chem B. 119, 2886-2896 (2015).
46. Brender, J. R. et al. The amyloidogenic SEVI precursor, PAP248-286, is highly unfolded in solution despite an underlying helical tendency. Biochim Biophys Acta. 1808, 1161-1169 (2011).
47. Brender, J. R. et al. Helical conformation of the SEVI precursor peptide PAP248-286, a dramatic enhancer of HIV infectivity, promotes lipid aggregation and fusion. Biophys J. 97, 2474-83 (2009).
48. Yagi, H., Kusaka, E., Hongo, K., Mizobata, T., Kawata, Y. Amyloid fibril formation of alpha-synuclein is accelerated by preformed amyloid seeds of other proteins: implications for the mechanism of transmissible conformational diseases. J. Biol. Chem. 280, 38609-38616 (2005).
49. Naiki, H., Higuchi, K., Hosokawa, M., Takeda, T. Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1. Anal. Biochem. 177, 244-249 (1989).
50. Ikemoto, Y. et al. Development of scattering near-field optical microspectroscopy apparatus using an infrared synchrotron radiation source. Optics Communications. 285, 2212-2217 (2012).